View in EDS

Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398].

Saved in:
Bibliographic Details
Title: Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398].
Authors: Martinon-Torres F; Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago, University of Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain., Wysocki J; Poznan University of Medical Sciences, Poland., Szenborn L; Wroclaw Medical University, Poland., Carmona-Martinez A; Instituto Hispalense de Pediatría, Sevilla, Spain., Poder A; Clinical Research Center, Tartu, Estonia., Dagan R; The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences of the Ben-Gurion University of the Negev, Beer-Sheva, Israel., Richmond P; Telethon Kids Institute and School of Medicine, The University of Western Australia, Crawley, WA 6009, Australia., Gilbert C; Merck & Co., Inc., Rahway, NJ, USA., Trudel MC; Merck Canada Inc., Kirkland, QC, Canada., Flores S; Merck & Co., Inc., Rahway, NJ, USA., Lupinacci R; Merck & Co., Inc., Rahway, NJ, USA., McFetridge R; Merck & Co., Inc., Rahway, NJ, USA., Wiedmann RT; Merck & Co., Inc., Rahway, NJ, USA., Chen Q; Merck & Co., Inc., Rahway, NJ, USA., Gerrits H; MSD B.V., OSS, the Netherlands., Banniettis N; Merck & Co., Inc., Rahway, NJ, USA. Electronic address: natalie.banniettis@merck.com., Musey L; Merck & Co., Inc., Rahway, NJ, USA., Bickham K; Merck & Co., Inc., Rahway, NJ, USA., Kaminski J; MSD (UK) Limited, London, United Kingdom.
Corporate Authors: V114-025 PNEU-PED-EU-1 study group
Source: Vaccine [Vaccine] 2025 Feb 27; Vol. 48, pp. 126628. Date of Electronic Publication: 2025 Jan 20.
Publication Type: Published Erratum
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39837003
AccessLevel: 2
PubTypeId: unknown
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398].
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Martinon-Torres+F%22">Martinon-Torres F</searchLink>; Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago, University of Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Wysocki+J%22">Wysocki J</searchLink>; Poznan University of Medical Sciences, Poland.<br /><searchLink fieldCode="AU" term="%22Szenborn+L%22">Szenborn L</searchLink>; Wroclaw Medical University, Poland.<br /><searchLink fieldCode="AU" term="%22Carmona-Martinez+A%22">Carmona-Martinez A</searchLink>; Instituto Hispalense de Pediatría, Sevilla, Spain.<br /><searchLink fieldCode="AU" term="%22Poder+A%22">Poder A</searchLink>; Clinical Research Center, Tartu, Estonia.<br /><searchLink fieldCode="AU" term="%22Dagan+R%22">Dagan R</searchLink>; The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences of the Ben-Gurion University of the Negev, Beer-Sheva, Israel.<br /><searchLink fieldCode="AU" term="%22Richmond+P%22">Richmond P</searchLink>; Telethon Kids Institute and School of Medicine, The University of Western Australia, Crawley, WA 6009, Australia.<br /><searchLink fieldCode="AU" term="%22Gilbert+C%22">Gilbert C</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Trudel+MC%22">Trudel MC</searchLink>; Merck Canada Inc., Kirkland, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Flores+S%22">Flores S</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Lupinacci+R%22">Lupinacci R</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22McFetridge+R%22">McFetridge R</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Wiedmann+RT%22">Wiedmann RT</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Chen+Q%22">Chen Q</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Gerrits+H%22">Gerrits H</searchLink>; MSD B.V., OSS, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Banniettis+N%22">Banniettis N</searchLink>; Merck & Co., Inc., Rahway, NJ, USA. Electronic address: natalie.banniettis@merck.com.<br /><searchLink fieldCode="AU" term="%22Musey+L%22">Musey L</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Bickham+K%22">Bickham K</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Kaminski+J%22">Kaminski J</searchLink>; MSD (UK) Limited, London, United Kingdom.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22V114-025+PNEU-PED-EU-1+study+group%22">V114-025 PNEU-PED-EU-1 study group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228406899%22">Vaccine</searchLink> [Vaccine] 2025 Feb 27; Vol. 48, pp. 126628. <i>Date of Electronic Publication: </i>2025 Jan 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Published Erratum
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8406899 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1873-2518 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220264410X%22">0264410X </searchLink><i>NLM ISO Abbreviation: </i>Vaccine <i>Subsets: </i>MEDLINE; PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39837003
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.vaccine.2024.126628
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 126628
    Titles:
      – TitleFull: Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398].
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Martinon-Torres F
      – PersonEntity:
          Name:
            NameFull: Wysocki J
      – PersonEntity:
          Name:
            NameFull: Szenborn L
      – PersonEntity:
          Name:
            NameFull: Carmona-Martinez A
      – PersonEntity:
          Name:
            NameFull: Poder A
      – PersonEntity:
          Name:
            NameFull: Dagan R
      – PersonEntity:
          Name:
            NameFull: Richmond P
      – PersonEntity:
          Name:
            NameFull: Gilbert C
      – PersonEntity:
          Name:
            NameFull: Trudel MC
      – PersonEntity:
          Name:
            NameFull: Flores S
      – PersonEntity:
          Name:
            NameFull: Lupinacci R
      – PersonEntity:
          Name:
            NameFull: McFetridge R
      – PersonEntity:
          Name:
            NameFull: Wiedmann RT
      – PersonEntity:
          Name:
            NameFull: Chen Q
      – PersonEntity:
          Name:
            NameFull: Gerrits H
      – PersonEntity:
          Name:
            NameFull: Banniettis N
      – PersonEntity:
          Name:
            NameFull: Musey L
      – PersonEntity:
          Name:
            NameFull: Bickham K
      – PersonEntity:
          Name:
            NameFull: Kaminski J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 27
              M: 02
              Text: 2025 Feb 27
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1873-2518
          Numbering:
            – Type: volume
              Value: 48
          Titles:
            – TitleFull: Vaccine
              Type: main
ResultId 1